News

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Bagsværd, Denmark and Boston, MA, US, 25 February 2026 – Novo Nordisk and Vivtex Corporation today announced a partnership to develop next-generation oral biologic medicines for obesity, diabetes and associated comorbidities. Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration,...

read more

InSphero and PharmaNest Form a Partnership to Advance Translational Fibrosis Research

InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems signed a partnership with PharmaNest Inc, a Princeton, NJ-based digital pathology company. This partnership uniquely positions InSphero’s in the space of the translational application of machine learning tools in combination with human pre-clinical models to decipher complex pathological phenotypes for the identification of effective therapies. A key challenge of these current unmet clinical needs is the prediction of the drug efficacy of complex fibrotic phenotypes in clinical...

read more

Industry Leaders Announce World’s First Microphysiological Systems Industry Association (IAMPS)

European microphysiological systems (MPS) industry leaders, Alveolix (Switzerland); BiomimX (Italy); Chiron (Netherlands); Dynamic42 (Germany); InSphero (Switzerland); MIMETAS (Netherlands); NETRI (France), React4Life (Italy) and TissUse (Germany), are announcing today the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world’s first industry association dedicated to represent MPS providers. IAMPS’ mission is...

read more

Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology

Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced it has entered into a strategic collaboration and exclusive option-to-license agreement with CSL, a global leader in developing and delivering high-quality...

read more